Abstract 971P
Background
The growing demand for hepatic resection in elderly hepatocellular carcinoma (HCC) patients highlights the need to understand the impact of preoperative frailty on surgical outcomes. This multicenter retrospective cohort study aimed to investigate the association between frailty and short-term and long-term outcomes following hepatic resection in elderly HCC patients.
Methods
We conducted a multicenter retrospective cohort study on elderly patients (≥70 years) who underwent curative-intent hepatic resection for HCC at 10 Chinese hospitals in China from 2012 to 2021. Frailty was assessed using the Clinical Frailty Scale (CFS), with frailty defined as CFS ≥ 5. Primary outcomes included overall survival (OS) and recurrence-free survival (RFS); secondary outcomes encompassed postoperative 30-day morbidity, 30-day mortality, and 90-day mortality. We compared these outcomes between patients with and without preoperative frailty.
Results
Of the 488 elderly patients, 148 (30.3%) were considered frail. Frail patients experienced significantly higher postoperative 30-day morbidity (68.9% vs. 43.2%), 30-day mortality (4.1% vs. 0.6%), and 90-day mortality (6.1% vs. 0.9%) than non-frail patients (all P<0.05). During a median follow-up of 37.7 months (IQR: 20.4-57.8), frail patients demonstrated significantly worse median OS (41.6 months [95% CI, 32.0-51.2] vs. 69.7 months [95% CI, 55.6-83.8]) and RFS (27.6 months [95% CI, 23.1-32.1] vs. 42.7 months [95% CI, 34.6-50.8]) compared to non-frail patients (both P<0.01). Multivariate Cox-regression analysis revealed frailty as a significant predictor for OS (HR 1.61, 95% CI 1.22-2.13, P=0.001) and RFS (HR 1.32, 95% CI 1.03-1.70, P=0.028).
Conclusions
Frailty was significantly associated with adverse short-term and long-term outcomes in elderly HCC patients undergoing hepatic resection. Our findings suggest that frailty assessment should be incorporated into perioperative and postoperative prognosis evaluation, and particular attention should be given to frail elderly patients undergoing this procedure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tian Yang.
Funding
National Natural Science Foundation of China; Dawn Project Foundation of Shanghai; Shanghai Health Academic Leader Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
735P - Causes of death in a complete cohort of testicular cancer patients diagnosed in Norway 1980-2009, with detailed treatment information
Presenter: Øivind Kvammen
Session: Poster session 18
736P - Residual masses after salvage chemotherapy in men with metastatic seminoma: The Semi-ResMass multicenter retrospective study
Presenter: Giulia Baciarello
Session: Poster session 18
737P - Vascular fingerprint tool to identify testicular cancer patients at high-risk for early cardiovascular events after cisplatin-based chemotherapy
Presenter: Andrea Meuleman
Session: Poster session 18
738P - Penile squamous cell carcinoma with high and very high tumor mutational burden (TMB): A genomic landscape and "real-world" clinical outcome study
Presenter: Joseph Jacob
Session: Poster session 18
739P - Penile squamous cell carcinoma tissue associated macrophages captured by multiplex immunfluorence are associated with clinical outcomes
Presenter: Jad Chahoud
Session: Poster session 18
827P - Mutational spectra of the Korean patients with germline predisposition in hematologic malignancies: Five years of experience at a tertiary university hospital
Presenter: In-Suk Kim
Session: Poster session 18
828P - Clinical features and outcomes of neurologic paraneoplastic syndromes in Hodgkin lymphoma
Presenter: Benjamin McCormick
Session: Poster session 18
829P - Age and sex related genomic profiles of follicular lymphoma
Presenter: Robin Imperial
Session: Poster session 18
830P - Isolation of cell-free DNA of patients with mucosa-associated lymphoid tissue (MALT) lymphoma
Presenter: Julia Berger
Session: Poster session 18
831P - Decitabine sensitized TP53-mutated diffuse large B cell lymphoma to R-CHOP treatment via activation of endogenous retrovirus
Presenter: Li Wang
Session: Poster session 18